 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || PF-07265807 / Pfizer
Trial completion date, Trial primary completion date, Metastases: Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - Apr 4, 2024
P1, N=67, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- || PF-07265807 / Pfizer
Enrollment closed, Enrollment change, Metastases: Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - Jul 21, 2023
P1, N=61, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024 Recruiting --> Active, not recruiting | N=161 --> 61
- Inlyta (axitinib) / Pfizer, PF-07265807 / Pfizer, sasanlimab (PF-06801591) / Pfizer
Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma (On Demand | Level 1, West Hall; Poster Board No. N1) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_702;
P1
The study started in late 2020 and is recruiting. Clinical trial information: NCT04458259.
- PF-07265807 / Pfizer, sasanlimab (PF-06801591) / Pfizer
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors. (On Demand | Level 1, West Hall; Poster Board No. P12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_932;
P1
The study began in Q4 2020 and is recruiting pts. Clinical trial information: NCT04458259.
- || PF-07265807 / Pfizer
Trial completion date, Trial primary completion date, Metastases: Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - Oct 12, 2022
P1, N=161, Recruiting, Sponsor: Pfizer
Clinical trial information: NCT04458259. Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- || PF-07265807 / Pfizer
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - Aug 31, 2021
P1, N=155, Recruiting, Sponsor: Pfizer
Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2024 --> Jun 2024 N=37 --> 155 | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023
- ||||| PF-07265807 / Pfizer
Preclinical, Monotherapy: PF-07265807 is a selective small-molecule inhibitor of the TAMKs MERTK and AXL. In preclinical models, PF-07265807 monotherapy shows antitumor activity that results in long-term cures and resistance to tumor re-challenge when combined with PD1 therapy (Twitter) - Jun 6, 2021
- ||||||| PF-07265807 / Pfizer
Clinical, P1 data: 🚨 On behalf of the co-investigators it is a pleasure to present 👉 Trials in progress: A phase 1, open-label, dose-escalation, PK, safety study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors. @ASCO #ASCO21 @OncoAlert (Twitter) - Jun 6, 2021
- PF-07265807 / Pfizer
[VIRTUAL] Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2728;
P1
Secondary endpoints: PK parameters of PF-07265807, objective response rate and duration of response . The study began enrolling pts in September 2020 and is still recruiting.
- PF-07265807 / Pfizer
[VIRTUAL] The potent and selective MERTK/AXL inhibitor PF-5807/ARRY-067 activates dendritic cells to cross-prime CD8+ T cells for anti-tumor activity () - Mar 11, 2021 - Abstract #AACR2021AACR_1282;
Therefore, we find that PF-5807 activates DCs to cross-prime CD8+ T cells, which are necessary for tumor control and are likely responsible for the establishment of tumor-specific memory T cells. PF-5807 is currently in an ongoing Phase I clinical trial in patients with advanced or metastatic solid tumors, with the intent to explore combination with anti-PD-1/anti-PD-L1 antibodies.
- || PF-07265807 / Pfizer
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - Dec 30, 2020
P1, N=37, Recruiting, Sponsor: Pfizer
PF-5807 is currently in an ongoing Phase I clinical trial in patients with advanced or metastatic solid tumors, with the intent to explore combination with anti-PD-1/anti-PD-L1 antibodies. Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Oct 2024 | Trial primary completion date: Mar 2023 --> Oct 2024
- || PF-07265807 / Pfizer
New P1 trial, Metastases: Study of PF-07265807 in Participants With Metastatic Solid Tumors. (clinicaltrials.gov) - Jul 6, 2020
P1, N=37, Not yet recruiting, Sponsor: Pfizer